Report #2835382

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: CO
Recovered: Unknown
Vaccinated: Feb 11, 2025
Onset: Mar 27, 2025
Days to onset: 44
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	944918	IM / LA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

Received Heplisav-B In Late February, and A Second Dose of Engerix Pediatric Dose Today; Initial report received on 27-Mar-2025. A medical assistant reported that a 57-year-old female (race, ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) as the first dose for hepatitis B immunization and received ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On 11-Feb-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (Lot# 944918, NDC # 43628-0003-05, expiration date not available)] intramuscularly in the left deltoid. On 27-Mar-2025, 44 days after having been vaccinated with HEPLISAV-B, the patient was given a pediatric dose of a hepatitis B vaccine [ENGERIX-B (Lot#, expiration date, site and route not reported)].. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.